Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor

被引:122
|
作者
Mirzabekov, T
Bannert, N
Farzan, M
Hofmann, W
Kolchinsky, P
Wu, LJ
Wyatt, R
Sodroski, J
机构
[1] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA
[4] Leukosite Inc, Cambridge, MA 02142 USA
关键词
D O I
10.1074/jbc.274.40.28745
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Seven-transmembrane segment, G protein-coupled receptors (GPCRs) play important roles in many biological processes in which pharmaceutical intervention may be useful. High level expression and native purification of GPCRs are important steps in the biochemical and structural characterization of these molecules. Here, we describe enhanced mammalian cell expression and purification of a codon-optimized variant of the chemokine receptor CCR5, a GPCR that plays a central role in the entry of the human immunodeficiency virus-1 (HIV-1) into immune cells. CCR5 could be solubilized in its native state as determined by its ability to be precipitated by 2D7, a conformation-dependent anti-CCR5 antibody, and by the HIV-1 gp120 envelope glycoprotein. The 2D7 antibody recognized immature and mature forms of CCR5 equally, whereas gp120 preferentially recognized the mature form, a result that underscores a role for posttranslational modification of CCR5 in its HIV-1 coreceptor function. The methods described herein contribute to the analysis of CCR5 and are likely to be applicable to many other GPCRs.
引用
收藏
页码:28745 / 28750
页数:6
相关论文
共 50 条
  • [31] Transcription factor GATA-1 potently represses the expression of the HIV-1 coreceptor CCR5 in human T cells and dendritic cells
    Sundrud, MS
    VanCompernolle, SE
    Eger, KA
    Bruno, TC
    Subramaniam, A
    Mummidi, S
    Ahuja, SK
    Unutmaz, D
    BLOOD, 2005, 106 (10) : 3440 - 3448
  • [32] CCR5 monoclonal antibodies for HIV-1 therapy
    Olson, William C.
    Jacobson, Jeffrey M.
    CURRENT OPINION IN HIV AND AIDS, 2009, 4 (02) : 104 - 111
  • [33] CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis
    Morris, L
    Cilliers, T
    Bredell, H
    Phoswa, M
    Martin, DJ
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2001, 17 (08) : 697 - 701
  • [34] Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5
    Agrawal, L
    VanHorn-Ali, Z
    Berger, EA
    Alkhatib, G
    BLOOD, 2004, 103 (04) : 1211 - 1217
  • [35] Choosing CCR5 or Rev siRNA in HIV-1
    H. Jose Arteaga
    Jorma Hinkula
    Iris van Dijk-Härd
    M. Sirac Dilber
    Britta Wahren
    Birger Christensson
    Abdalla J. Mohamed
    C. I. Edvard Smith
    Nature Biotechnology, 2003, 21 : 230 - 231
  • [36] HIV-1 infection and CCR5Δ32 homozygosis
    Ballana, Ester
    Este, Jose A.
    FUTURE VIROLOGY, 2012, 7 (07) : 653 - 658
  • [37] CCR5 as target for HIV-1 gene therapy
    Nazari, Reza
    Joshi, Sadhna
    CURRENT GENE THERAPY, 2008, 8 (04) : 264 - 272
  • [38] Identifying CCR5 coreceptor populations permissive for HIV-1 entry and productive infection: implications for in vivo studies
    Matthew Weichseldorfer
    Yutaka Tagaya
    Marvin Reitz
    Anthony L. DeVico
    Olga S. Latinovic
    Journal of Translational Medicine, 20
  • [39] Genetic variation within the gene encoding the HIV-1 CCR5 coreceptor in two South African populations
    Picton, Anabela C. P.
    Paximadis, Maria
    Tiemessen, Caroline T.
    INFECTION GENETICS AND EVOLUTION, 2010, 10 (04) : 487 - 494
  • [40] Evolution of Multiple Domains of the HIV-1 Envelope Glycoprotein during Coreceptor Switch with CCR5 Antagonist Therapy
    Du, Yueqi
    Wu, Ellen
    Gao, Xiang
    Zhang, Jie
    Martin, John C.
    Rosa, Bruce A.
    Mitreva, Makedonka
    Ratner, Lee
    MICROBIOLOGY SPECTRUM, 2022, 10 (04):